{"entity":{"id":"mga","kind":"target","name":"MGA","aka":["MAX dimerization protein MGA","MAX gene-associated protein","KIAA0518","MAD5","MXD5","FLJ12634"],"tldr":"MGA (MAX gene-associated protein) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Mesothelioma, Prostate cancer, Diffuse large B-cell lymphoma and 3 more.","summary":"Functions as a dual-specificity transcription factor, regulating the expression of both MAX-network and T-box family target genes. Functions as a repressor or an activator. Binds to 5'-AATTTCACACCTAGGTGTGAAATT-3' core sequence and seems to regulate MYC-MAX target genes.\n\nCIViC holds 1 clinical evidence item and 0 assertions across 1 variant. IntOGen calls it a driver in 5 cohorts (0 activating, 5 loss-of-function), covering Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma, Lung Adenocarcinoma, Pleural Mesothelioma, Prostate Adenocarcinoma.","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:14010","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:14010"},{"label":"UniProt Q8IWI9","url":"https://www.uniprot.org/uniprotkb/Q8IWI9/entry"},{"label":"NCBI Gene 23269","url":"https://www.ncbi.nlm.nih.gov/gene/23269"},{"label":"Ensembl ENSG00000174197","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000174197"}],"tags":["cancer-genes-wave"],"related":["civic","intogen"],"cancers":["mesothelioma","prostate","dlbcl","cll","nsclc","pleural-mesothelioma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it a loss-of-function (LoF) driver in 5 cohorts; CIViC holds 1 clinical evidence items on its variants. Evidence tier \"clinical-evidence\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"MGA","role":["tumour-suppressor","biomarker"],"evidenceTier":"clinical-evidence","sources":[{"label":"HGNC HGNC:14010","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:14010","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt Q8IWI9","url":"https://www.uniprot.org/uniprotkb/Q8IWI9/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene MGA","url":"https://civicdb.org/features/9427","note":"1 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma (GraphQL API, CC0)"},{"label":"IntOGen MGA","url":"https://www.intogen.org/search?gene=MGA","note":"driver in 5 cohorts (Act 0, LoF 5); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0"}],"hgnc":"HGNC:14010","ensembl":"ENSG00000174197","uniprot":"Q8IWI9","entrez":"23269","biology":"Functions as a dual-specificity transcription factor, regulating the expression of both MAX-network and T-box family target genes. Functions as a repressor or an activator. Binds to 5'-AATTTCACACCTAGGTGTGAAATT-3' core sequence and seems to regulate MYC-MAX target genes. Suppresses transcriptional activation by MYC and inhibits MYC-dependent cell transformation. Function activated by heterodimerisation with MAX. This heterodimerisation serves the dual function of both generating an E-box-binding heterodimer and simultaneously blocking interaction of a corepressor. Location: Nucleus (UniProt). Locus 15q15 (HGNC).","whereFound":["Mesothelioma: IntOGen driver in 1 cohort (PLMESO)","Prostate cancer: IntOGen driver in 1 cohort (PRAD)","Diffuse large B-cell lymphoma: CIViC evidence names this disease","Chronic lymphocytic leukaemia: IntOGen driver in 2 cohorts (CLLSLL)","Non-small-cell lung cancer: IntOGen driver in 1 cohort (LUAD)","Pleural mesothelioma: IntOGen driver in 1 cohort (PLMESO)"],"targetClass":"tumor-suppressor","prevalence":[]},"route":"/targets/mga/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"},{"id":"intogen","kind":"collection","name":"IntOGen","route":"/collections/intogen/"}],"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"mesothelioma","kind":"cancer","name":"Mesothelioma","route":"/cancers/mesothelioma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"pleural-mesothelioma","kind":"cancer","name":"Pleural mesothelioma","route":"/cancers/pleural-mesothelioma/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}]}}